UK's drug-cost watchdog recommends use of GSK unit's HIV prevention drug

Core Viewpoint - The UK's drugs cost-effectiveness watchdog has positively recommended ViiV Healthcare's HIV drug, facilitating access to this preventive medicine through the state health system in England and Wales [1] Group 1 - The recommendation from the UK's cost-effectiveness watchdog is expected to enhance the availability of ViiV Healthcare's HIV drug [1] - This decision signifies a crucial step in public health policy, aiming to improve preventive measures against HIV [1]